repeatedli
take
small
amount
noxiou
substanc
honey
theriaca
practic
dissimilar
certain
contemporari
holist
ritual
sinc
introduct
variol
near
east
earli
eighteenth
centuri
use
cowpox
viru
variola
public
concern
safeti
efficaci
vaccin
concept
safeti
chang
time
reaction
common
risk
seriou
diseas
great
longer
accept
although
often
exagger
individu
passion
group
champion
doctrin
sever
today
concern
seem
justifi
especi
recogn
problem
vaccin
address
light
exist
knowledg
experi
rapidli
chang
attitud
toward
pet
valu
health
care
provok
vigor
widespread
discuss
use
vaccin
small
anim
practic
priest
schultz
smith
tizzard
illustr
fullday
session
devot
vaccin
practic
juli
annual
meet
avma
cornel
felin
practition
seminar
recent
symposium
european
symposium
pet
vaccinolog
held
franc
septemb
ideal
world
real
presum
problem
companion
anim
vaccin
would
address
quickli
respons
industri
govern
regulatori
offici
veterinari
profess
soon
identifi
unfortun
problem
often
neglect
avoid
circumst
contribut
confus
creation
myth
often
enhanc
differ
view
expert
sometim
form
conclus
limit
data
bias
sampl
design
misfortun
vaccin
well
document
literatur
appel
gillespi
carmichael
carmichael
martin
rikula
et
al
tizzard
wilbur
et
al
wilson
et
al
often
becom
elev
catastroph
howev
especi
advoc
radic
philosophi
ignor
benefit
provid
vaccin
concern
sometim
led
senseless
conclus
vaccin
danger
direct
indirect
caus
chronic
ill
vaccinosi
vaccinos
claim
rang
devast
immun
system
lazi
bowel
diseas
bloat
stain
teeth
ulcer
chronic
gastroenter
autoimmun
hemolyt
anaemia
seizur
list
condit
cite
duval
giger
pitcairn
priest
staritamehan
yarnal
howev
truth
passion
indiffer
other
advoc
holist
vaccin
practic
inan
may
seem
may
actual
servic
pet
fancier
bring
issu
fore
larg
ignor
unfortun
legitim
safeti
efficaci
problem
sometim
disregard
major
misfortun
occur
nevertheless
experienc
rampant
distemp
outbreak
prior
amaz
argument
present
critic
especi
holist
believ
within
year
advent
efficaci
distemp
vaccin
diseas
practic
disappear
vaccin
popul
reappear
whenev
vaccin
diminish
undeni
progress
made
suppress
canin
distemp
infecti
hepat
recent
control
canin
parvoviru
pandem
remark
short
period
time
howev
recent
outbreak
distemp
scandinavia
year
epizoot
alaska
northern
quebec
illustr
may
occur
distemp
vaccin
efficaci
vaccin
use
diminish
veterinarian
public
becom
sophisticatedand
litigi
want
know
fact
treatment
use
unfortun
mani
essenti
fact
regard
vaccin
lack
myth
continu
flourish
question
commonli
ask
dog
ownersbreed
veterinarian
usual
complex
vaccin
avail
dog
necessari
vaccin
safe
young
pup
effect
prevent
diseas
live
inactiv
vaccin
produc
steril
immun
interrupt
transmiss
soon
immun
occur
vaccin
long
endur
vaccin
continu
develop
diseas
still
poorli
understood
mani
agent
packag
multicompon
vaccin
consequ
well
establish
immun
system
respond
normal
sever
differ
antigen
issu
seem
persist
howev
combin
vaccin
inadequ
field
trial
data
prior
releas
given
rise
seriou
consequ
regard
safeti
unfortun
answer
question
often
reflect
individu
experi
vest
interest
disinclin
state
true
answer
known
estim
offic
visit
veterinarian
associ
vaccin
sever
vaccin
dog
cat
licens
poor
question
efficaci
yet
continu
produc
promot
exampl
leptospira
bacterin
canin
coronaviru
ccv
vaccin
recent
past
sever
canin
parvoviru
type
vaccin
new
improv
vaccin
introduc
almost
yearli
yet
even
perfunctori
examin
reveal
spars
amount
data
often
overst
claim
particular
product
hand
question
pose
veterinarian
dog
owner
oppos
vaccin
philosoph
ground
often
defi
factual
answer
pauciti
publish
result
question
often
base
percept
valid
data
avail
also
mani
individu
accept
realiti
vaccin
medic
practic
sustain
risk
larg
extent
problem
standard
veterinari
vaccin
resist
solut
complex
inher
number
differ
vaccin
viral
strain
avail
pet
anim
poorli
character
share
belief
expect
vaccin
turn
point
articl
outlin
person
view
experi
note
unsettl
problem
point
difficulti
resolv
commonli
ask
question
notwithstand
awar
remark
littl
impact
unless
veterinarian
concern
dog
vaccin
show
concern
rais
felin
practition
associ
act
gain
better
understand
vaccin
work
realist
appreci
problem
occur
might
remedi
veterinari
vaccin
continu
develop
empir
technolog
avail
new
vaccin
doubtless
continu
develop
includ
subunit
vaccin
vector
recombin
vaccin
delet
mutant
nucleic
acid
plasmid
dna
vaccin
perhap
even
recombin
nosod
sic
made
avail
howev
merit
evalu
present
use
product
mere
sake
novelti
recombin
vaccin
exampl
vacciniavector
rabi
wildlif
recent
licens
canari
poxvector
distemp
vaccin
lyme
diseas
vaccin
shown
merit
util
safeti
case
superior
efficaci
except
modifi
live
viru
mlv
vaccin
common
product
use
worldwid
appel
carmichael
vaccin
compris
viru
strain
select
spontan
mutant
emerg
nativ
viral
popul
repeat
passag
cell
cultur
laboratori
host
major
vaccin
consist
viral
popul
contain
multipl
mutat
canin
vaccin
strain
biolog
clone
suppress
gener
nonimmun
mutant
laboratori
passag
vaccin
mutant
grow
intend
host
yet
replic
restrict
critic
tissu
constitut
vaccin
differ
degre
loss
natur
virul
attenu
viru
nonimmun
mutant
also
may
emerg
laboratori
passag
variant
may
fail
grow
natur
host
yet
prolifer
luxuriantli
tissu
cultur
chick
embryo
attenu
mean
reduct
absolut
loss
capac
produc
diseas
safeti
problem
may
reveal
extens
field
test
conduct
unfortun
occur
product
licens
market
conspicu
exampl
failur
larg
number
dog
die
suffer
seriou
ill
follow
introduct
live
canin
coronaviru
vaccin
martin
wilson
et
al
also
vaccin
judg
harmless
one
speci
may
provok
ill
anoth
one
appel
carmichael
tizzard
uncertainti
absolut
safeti
certain
vaccin
exampl
distemp
vaccin
strain
propag
canin
cell
cultur
live
viral
vaccin
recommend
wildlif
speci
pregnant
anim
unwean
pup
pup
ill
yet
breeder
veterinarian
continu
vaccin
pregnant
dam
pup
earli
week
age
use
vaccin
pet
speci
safeti
inform
limit
eg
ferret
efficaci
problem
persist
certain
primari
vaccin
canin
parvoviru
vaccin
certain
canin
distemp
product
appel
gillespi
carmichael
carmichael
carmichael
schultz
schultz
howev
recent
improv
sever
canin
vaccin
especi
parvoviru
vaccin
previous
poor
margin
efficaci
greatli
improv
appear
provok
good
immun
respons
whether
improv
sustain
depend
larg
measur
care
taken
vaccin
produc
select
conserv
seed
stock
canin
distemp
virtual
licens
canin
distemp
cd
vaccin
consist
live
attenu
viral
strain
appel
appel
gillespi
carmichael
major
produc
eggadapt
avian
cell
cultureadapt
onderstepoort
strain
rockborn
strain
propag
canin
cell
cultur
rockborn
et
al
rockborn
strain
produc
legitim
european
compani
author
professor
gunnar
rockborn
g
rockborn
person
commun
viru
undergon
passag
cell
cultur
wherea
viru
sever
us
vaccin
use
lower
passag
level
thu
design
rockborn
cd
vaccin
strain
misrepres
sever
author
past
includ
certain
product
also
claim
contain
attenu
snyder
hill
strain
also
grown
canin
cell
cultur
ferretorigin
strain
cultiv
avian
cell
cultur
difficult
determin
origin
viral
strain
cd
vaccin
strain
given
novel
design
manufactur
genet
marker
regardless
viral
strain
employ
attenu
cd
vaccin
prove
highli
effect
administ
dog
lack
matern
immun
variabl
effect
dog
low
level
matern
antibodi
note
earlier
recogn
problem
certain
cd
vaccin
especi
propag
canin
cell
cultur
variabl
occurr
postvaccin
pv
enceph
actual
risk
unknown
appel
appel
appel
gillespi
carmichael
cd
vaccin
virul
sever
zoo
wildlif
speci
consid
pet
eg
ferret
skunk
raccoon
also
revers
virul
attenu
rockborn
cd
strain
demonstr
serial
passag
dog
dog
lung
macrophag
appel
canin
celladapt
vaccin
recommend
pup
less
week
age
wildlif
speci
greater
risk
postvaccin
enceph
field
experi
demonstr
enhanc
virul
cd
vaccin
produc
canin
cell
cultur
administ
combin
certain
virus
conspicu
canin
adenoviru
type
ich
live
ccv
vaccin
carmichael
martin
wilson
et
al
notwithstand
risk
note
earlier
rockborn
strain
passag
level
use
laboratori
princip
experiment
vaccin
year
vaccin
adjust
tcddodos
sinc
minim
immun
dose
mid
rockborn
strain
instanc
case
postvaccin
enceph
observ
field
use
howev
laboratori
experi
vaccin
dose
vaccin
given
togeth
live
enceph
frequent
occurr
day
postvaccin
field
report
indic
frequenc
postvaccin
cd
enceph
diminish
greatli
substitut
combin
vaccin
one
reason
advoc
substitut
canin
vaccin
addit
mark
total
reduct
postvaccin
blue
eye
occur
frequent
vaccin
manufactur
util
canin
cellgrown
cdv
therefor
determin
optim
safe
dose
person
view
vaccin
mid
indic
packag
insert
seem
import
cd
vaccin
differ
reason
see
cd
vaccin
titer
kept
low
excel
immun
provid
cd
vaccin
grown
canin
cell
would
probabl
attend
accept
risk
pv
reaction
durat
immun
data
commerci
distemp
vaccin
limit
one
studi
baker
institut
l
e
carmichael
unpublish
result
nine
beagl
vaccin
rockborn
cd
strain
maintain
strict
isol
dog
high
level
neutral
antibodi
year
later
also
recent
confirm
immun
sn
titer
male
dog
vaccin
commerci
multipl
vaccin
kept
breed
stock
kennel
maintain
strict
isol
nevertheless
rate
immun
follow
vaccin
differ
cd
vaccin
appel
appel
gillespi
carmichael
rikula
et
al
canin
vaccin
matern
antibodi
interfer
immun
recent
substanti
differ
report
abil
cd
vaccin
immun
pup
similar
level
matern
antibodi
week
age
schultz
earli
studi
durat
antibodi
persist
level
estim
ensur
immun
neutral
antibodi
titer
wane
within
year
dog
vaccin
chick
embryoadapt
lederl
low
passag
cd
strain
year
later
anoth
antibodi
titer
baker
et
al
baker
et
al
limit
data
appear
basi
common
practic
annual
revaccin
whether
sn
titer
test
done
requir
protect
uncertain
state
sn
titer
protect
appel
gillespi
gorham
neutral
antibodi
low
egg
passag
onderstepoort
strain
also
report
last
year
almost
dog
kept
isol
prydi
sinc
distemp
vaccin
efficaci
gener
improv
recent
year
seem
reason
without
radic
discontinu
recommend
annual
vaccin
first
year
life
limit
vaccin
interv
notwithstand
veterinarian
dog
breeder
like
continu
annual
vaccin
pecuniari
reason
minimum
immun
dose
canin
vaccin
strain
determin
eggadapt
cd
strain
appear
vari
somewhat
efficaci
caninecel
adapt
strain
vari
capac
provok
pv
enceph
rockborntyp
strain
probabl
contain
mid
unless
safeti
ensur
durat
immun
data
need
vaccin
especi
propag
chick
embryo
vero
cell
appear
provok
shorter
durat
immun
vaccin
howev
data
scant
data
essenti
formul
ration
recommend
safeti
caninecel
grown
rockborntyp
includ
snyder
hill
strain
rigor
studi
especi
use
combin
agent
need
effect
nonliv
cd
vaccin
especi
wildlif
speci
promis
experi
recombin
canarypox
distemp
product
protect
dog
challeng
virul
distemp
viru
suggest
possibl
success
vaccin
taylor
et
al
one
recombin
cd
product
recent
licens
unit
state
unequivoc
recommend
withheld
field
studi
demonstr
efficaci
durat
immun
sever
vaccin
develop
infect
immun
respons
data
b
strain
limit
except
brief
period
week
follow
vaccin
immun
believ
antibodi
mediat
hemagglutinationinhibit
hi
titer
consid
protect
carmichael
carmichael
carmichael
carmichael
et
al
pollock
carmichael
howev
serolog
test
standard
comparison
antibodi
titer
differ
laboratori
meaning
luffet
al
inactiv
mlv
vaccin
avail
countri
immun
dog
although
inactiv
vaccin
provid
limit
protect
infect
dog
may
exempt
diseas
sever
month
carmichael
pollock
carmichael
like
distemp
report
actual
durat
immun
inactiv
vaccin
limit
known
whether
immunolog
memori
provid
immun
beyond
period
antibodi
declin
detect
level
also
known
whether
kill
vaccin
perform
similar
manner
sinc
magnitud
antibodi
respons
relat
amount
viral
antigen
administ
inactiv
vaccin
interrupt
transmiss
virul
viru
except
belief
period
time
month
recommend
larg
number
dog
rais
breed
kennel
pet
shop
anim
shelter
dog
high
risk
exposur
show
field
trial
obviou
inactiv
vaccin
follow
mlv
vaccin
revers
antibodi
engend
kill
vaccin
neutral
live
viru
latter
instanc
kill
vaccin
would
wast
mlv
vaccin
immun
efficaci
modifiedl
vaccin
highli
success
prevent
parvoviru
infect
administ
seroneg
pup
dog
low
antibodi
titer
normal
engend
rapid
endur
immun
probabl
immun
persist
sever
year
hi
antibodi
titer
persist
period
long
year
dog
vaccin
one
strain
cornel
lp
strain
recent
test
male
dog
receiv
commerci
product
combin
vaccin
maintain
commerci
specif
pathogenfre
coloni
titer
year
later
similar
studi
vaccin
publish
test
done
laboratori
reveal
serum
hi
antibodi
titer
dog
receiv
certain
commerci
vaccin
declin
within
year
thu
differ
observ
vaccin
sever
one
test
earlier
replac
new
gener
product
cd
princip
caus
vaccin
failur
pup
matern
antibodi
interfer
ampli
exploit
biolog
produc
promot
new
vaccin
claim
immun
pup
earlier
compet
product
realiti
live
viru
vaccin
differ
capac
evad
low
level
antibodi
vaccin
shown
immun
pup
time
matern
antibodi
level
prevent
infect
virul
viru
concept
critic
period
window
vulner
develop
describ
period
time
pup
becom
suscept
infect
virul
viru
respond
unpredict
vaccin
carmichael
pollock
carmichael
critic
period
shown
rang
week
briefer
vaccin
other
vaccin
may
immun
pup
earlier
other
regardless
age
carmichael
carmichael
hoskin
et
al
schultz
failur
respond
efficaci
vaccin
relat
prevaccin
antibodi
titer
age
modifi
live
vaccin
report
caus
advers
reaction
myth
immunosuppress
virul
vaccin
viru
discredit
brunner
swango
phillip
schultz
inde
recent
studi
japan
indic
modifi
live
vaccin
enhanc
cellular
immun
respons
vaccin
given
dog
prior
surgeri
prevent
postsurg
immunosuppress
attend
use
halothan
anaesthesia
taura
et
al
despit
gener
benefit
deriv
vaccin
consist
efficaci
recur
problem
sever
commerci
mlv
vaccin
studi
laboratori
found
effect
time
launch
later
poor
efficaci
like
due
genet
heterogen
seed
stock
occurr
prompt
new
product
includ
vaccin
prepar
isol
repres
variant
b
origin
howev
evid
vaccin
prepar
recent
type
discern
advantag
efficaci
vaccin
prepar
origin
isol
usda
master
seed
principl
appear
function
well
vaccin
principl
may
sound
nt
alway
work
practic
reason
document
vaccin
strain
mutant
virus
fail
provok
immun
often
predomin
sever
passag
cell
cultur
fig
vaccin
examin
two
except
consist
mix
viral
popul
manufactur
therefor
prepar
seed
viru
biolog
clone
stock
select
clone
shown
immun
stabl
subsequ
cell
cultur
passag
seed
stock
vaccin
term
high
titer
vaccin
promot
advertis
term
littl
mean
minim
immun
dose
reveal
year
ago
test
two
wide
use
commerci
vaccin
viral
infect
titer
yet
provok
low
antibodi
respons
spf
dog
product
supplant
new
gener
vaccin
appear
past
year
vaccin
improv
substanti
casesoutbreak
report
unvaccin
dog
breed
kennel
anim
shelter
anim
vaccin
ineffect
vaccin
pup
interf
level
matern
antibodi
time
vaccin
puppi
contamin
kennel
fig
plaqu
variant
immunogen
clone
vaccin
origin
vaccin
viru
popul
predominantli
small
plaqu
sp
approxim
larg
plaqu
lp
vaccin
immun
pup
tcdso
viru
tcdo
select
sp
variant
fail
provok
hi
antibodi
respons
pup
even
dose
contrast
lp
variant
produc
strong
hi
antibodi
respons
within
day
vaccin
greatest
risk
infect
especi
stringent
hygien
practic
claim
vaccin
immun
pup
effici
particular
age
mislead
failur
respond
good
vaccin
relat
prevaccin
antibodi
level
age
also
never
observ
failur
suscept
dog
respond
efficaci
cd
vaccin
regardless
breed
eg
rottweil
studi
laboratori
nearli
field
sera
breedingag
dog
indic
approxim
would
expect
respond
week
age
hand
studi
vaccin
responseversusag
report
higher
success
rate
week
age
pup
kennel
dam
antibodi
titer
probabl
low
result
vaccin
rather
infect
hoskin
et
al
larson
schultz
schultz
control
initi
month
pup
life
base
stringent
manag
prudent
vaccinationmpup
isol
much
possibl
kept
sanitari
environ
avail
depend
good
vaccin
essenti
forego
remark
notwithstand
gener
success
vaccin
control
canin
parvoviru
infect
remark
improv
vaccin
efficaci
past
year
inspir
confid
parvovir
infect
continu
uncommon
vaccin
dog
rear
hygien
environ
inactiv
mlv
heterotyp
felin
parvoviru
vaccin
current
avail
homolog
mlv
vaccin
recommend
dog
interrupt
virul
transmiss
although
mlv
vaccin
regard
efficaci
document
safeti
problem
parvoviru
vaccin
year
sinc
introduct
note
also
attempt
boost
low
antibodi
titer
ie
hi
titer
ineffectu
vaccin
seed
stock
strain
biolog
clone
provid
uniform
stabl
viral
popul
order
ensur
constant
efficaci
would
seem
benefici
consid
primari
vaccin
pup
less
month
age
contain
cd
compon
multipl
vaccin
suggest
week
age
unless
pup
high
risk
respiratori
infect
eg
anim
shelter
pet
shop
etc
efficaci
distemp
vaccin
shown
provid
immun
least
year
revaccin
year
first
year
seem
conserv
strategi
parvoviru
vaccin
except
safe
dog
develop
sign
symptom
parvoviru
infect
within
day
vaccin
consid
infect
virul
viru
prior
time
vaccin
still
common
occurr
parvoviru
like
present
environ
eg
puppi
mill
pet
shop
dog
show
anim
shelter
veterinari
clinic
canin
infect
caus
ccv
viru
may
infect
cat
dog
occur
sporad
case
kennel
outbreak
mild
explos
appel
binn
et
al
pastoret
pollock
carmichael
tennant
et
al
although
ccv
frequent
observ
electron
microscopi
em
fece
normal
diarrheic
dog
true
role
ccv
play
canin
enter
ill
need
vaccin
yet
agre
howev
million
dose
sold
diseas
associ
ccv
usual
attend
low
mortal
occasion
death
occur
young
pup
dog
stress
intens
train
crowd
shelter
addit
enter
pathogen
seem
greater
risk
ill
biolog
ccv
close
rel
cat
pig
still
unclear
serolog
crossreact
demonstr
ccv
felin
infecti
peritonitisfelin
enter
coronaviru
fecv
transmiss
gastroenter
swine
crossprotect
report
ccv
fecv
coyn
may
report
ccv
case
report
epizootiolog
studi
ccv
particl
diarrheic
fece
rang
normal
stool
preval
rescu
kennel
rimmelzwaan
tennant
et
al
vieler
herbst
control
studi
netherland
detect
ccv
elisa
test
normal
stool
diarrheic
stool
rimmelzwaan
case
rare
report
sinc
usual
mild
except
infrequ
outbreak
fatal
case
usual
young
pup
laboratori
studi
confirm
mix
infect
ccv
result
sever
diseas
caus
either
viru
alon
appel
argument
commonli
use
justifi
use
ccv
vaccin
howev
report
vaccin
dog
ccv
vaccin
prevent
sever
manifest
concurr
close
space
infect
virus
one
studi
possibl
benefit
inactiv
ccv
vaccin
prevent
seriou
consequ
attend
infect
ccv
fail
demonstr
protect
appel
unpublish
result
also
dual
infect
appear
rare
vaccin
dog
result
extens
use
vaccin
inactiv
live
ccv
vaccin
avail
carmichael
coyn
may
edward
et
al
fulker
et
al
histori
ccv
vaccin
convolut
without
misfortun
first
licens
modifi
live
ccv
vaccin
rescind
shortli
introduct
sever
advers
reaction
lesion
resembl
fip
martin
reaction
occur
estim
vaccin
pup
gener
one
week
age
inactiv
ccv
vaccin
licens
also
withdrawn
market
shortli
issu
inadequ
efficaci
addit
second
licens
modifi
live
ccv
product
combin
canin
cellgrown
cd
vaccin
withdrawn
high
frequenc
post
vaccin
cd
enceph
vaccin
sinc
reformul
exclud
distemp
compon
appear
contribut
problem
interestingli
latter
ccv
vaccin
strain
licens
use
california
market
year
combin
distemp
vaccin
manufactur
affirm
advers
reaction
recent
licens
ccv
vaccin
compris
kill
fecv
product
inform
vaccin
well
other
limit
mainli
promot
inform
statu
ccv
infect
controversi
sinc
authent
case
outbreak
seldom
report
notwithstand
januari
made
sever
isol
ccv
outbreak
mild
enter
diseas
kennel
new
jersey
breed
train
dog
blind
interest
find
recent
isol
differ
previou
isol
failur
grow
felin
cell
cultur
lack
affin
aminopeptidasen
cell
receptor
typic
coronavirus
cat
dog
pig
human
studi
tresnan
et
al
tresnan
person
commun
would
seem
therefor
develop
distribut
ccv
vaccin
mainli
result
market
decis
clearli
demonstr
need
hand
factual
inform
ccv
diseas
limit
present
seem
inadequ
medic
justif
recommend
use
coronaviru
vaccin
dog
research
result
avail
lesson
experi
ccv
vaccin
veterinarian
cautiou
administ
new
product
especi
littl
data
avail
requir
product
licens
import
canin
viral
infect
distemp
problem
variabl
cd
vaccin
safeti
efficaci
persist
cd
vaccin
greatli
reduc
preval
diseas
case
vaccin
dog
rare
canin
hepat
ich
infect
also
control
well
vaccin
year
rare
sporad
case
seen
usual
occur
unvaccin
dog
vaccin
therefor
continu
given
sinc
prove
safe
effect
prevent
hepat
well
adenovir
tracheobronch
failur
vaccin
would
like
result
increas
case
ich
seriou
diseas
never
signific
distemp
cpv
infect
vaccin
often
question
complex
domin
opinion
ye
smith
question
respond
unequivoc
howev
sinc
manufactur
employ
differ
strain
vari
immun
capac
probabl
durat
immun
question
frequent
distemp
time
mani
veterinarian
test
batch
vaccin
use
provid
preand
postvaccin
sera
compet
diagnost
laboratori
practic
appear
benefit
veterinarian
dog
well
qualiti
vaccin
unfortun
mani
owner
veterinarian
seem
hold
view
infecti
diseas
parvoviru
infect
control
frequent
vaccin
alon
common
practic
dog
breeder
vaccin
anim
sever
time
year
senseless
revaccin
distemp
parvoviru
infect
suggest
year
age
recommend
regard
frequenc
vaccin
given
time
unclear
sinc
distemp
vaccin
probabl
provid
immun
endur
sever
year
vaccin
interv
first
year
seem
reason
practic
data
durat
immun
becom
avail
mani
kind
vaccin
promot
dog
distemp
parvoviru
vaccin
essenti
canin
adenoviru
vaccin
recommend
sinc
case
brought
attent
recent
year
unvaccin
dog
vaccin
respiratori
infect
recommend
dog
especi
kennel
board
need
clearli
establish
coronaviru
vaccin
lyme
diseas
vaccin
see
use
prevent
ill
area
diseas
exist
unnecessari
elsewher
sinc
dog
respond
rapidli
appropri
antibiot
current
leptospira
bacterin
without
benefit
sinc
contain
serovar
fail
protect
area
note
lyme
diseas
ld
consid
newer
recombin
ospa
vaccin
avail
appear
safe
effect
least
year
caus
vaccineinduc
postvaccin
lame
document
certain
wholecel
lyme
diseas
bacterin
lyme
diseas
vaccin
restrict
dog
enter
endem
area
infest
tick
resid
ld
case
occur
midatlant
northeastern
state
six
midwestern
state
michigan
minnesota
wisconsin
smaller
percentag
restrict
area
northern
california
pacif
northwest
leptospirosi
also
discuss
vaccin
commonli
report
caus
anaphylaxi
current
vaccin
contain
serovar
preval
region
vast
major
case
diagnos
new
york
state
diagnost
lab
cornel
grippotyphosa
pomona
serovar
recent
case
caus
canicola
icterohemorrhagia
serovar
leptospirosi
import
diseas
dog
urgent
need
research
develop
safer
vaccin
contain
preval
serovar
mexico
dog
may
infect
sever
serovar
canin
vaccin
contain
serovar
conditio
sine
qua
non
avail
consist
good
vaccin
without
standard
vaccin
seem
difficult
formul
gener
vaccin
recommend
effort
direct
improv
standard
import
vaccin
current
use
develop
new
product
unless
need
demonstr
public
becom
increasingli
awar
vaccin
problem
perhap
even
benefit
vaccin
realiti
vaccin
carri
risk
fulli
perceiv
mani
owner
veterinarian
altern
veterinari
medicin
grow
realiti
practic
taught
veterinari
colleg
question
pertain
vaccin
safeti
efficaci
continu
vex
veterinarian
vaccinologist
vaccin
produc
address
need
better
appreci
risk
advers
reaction
duval
giger
final
issu
discuss
recommend
might
made
littl
influenc
unless
biolog
manufactur
regulatori
offici
exercis
greater
respons
control
vaccin
qualiti
could
encourag
appoint
committe
unbias
expert
review
vaccin
diseas
provid
recommend
base
avail
evid
view
discuss
meet
sever
occas
past
year
larg
neglect
consider
involv
industri
interest
indiffer
overburden
govern
author
trust
veterinarian
dog
owner
advertis
vaccin
vaccin
guidelin
physician
supervis
american
academi
pediatr
committe
infecti
diseas
advisori
committe
immun
practic
advis
medic
profess
regulatori
author
holm
veterinari
profess
insist
respons
advisori
council
concern
question
regard
vaccin
continu
met
conflict
opinion
open
door
nosod
thuja
whose
benefit
seem
understood
use
profit
